Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Los términos de búsqueda han de ser en inglés.

Diagnóstico rápido de enfermedades infecciosas causadas por Staphylococcus aureus


Oferta Tecnológica
Dos centros de investigación españoles han desarrollado un método inmunoquímico para el diagnóstico de infecciones causadas por Staphylococcus aureus. El inmunoensayo es rápido y eficiente, con bajo LOD y adaptable a dispositivos point-of-care. El ensayo se basa en el uso de inmunoreactivos y anticuerpos policlonales capaces de detectar selectivamente la pared celular de S. aureus. Se buscan empresas interesadas en licenciar la patente y establecer acuerdos de colaboración en materia de investigación para desarrollar sus aplicaciones.


Rapid diagnosis of infectious diseases caused by Staphylococcus aureus
Two Spanish public research institutions have developed an immunochemical method for diagnosis of infections produced by Staphylococcus aureus. The immunoassay is fast and efficient, with low LOD and adaptable to point-of care devices.

Companies interested in patent licensing and/or in a research collaboration for the development of its applications are sought.
Staphylococcus aureus is an important cause of community and hospital acquired infections, responsible for various diseases including mild skin infections (impetigo), wound infections or blood stream infections (toxic shock syndrome, etc).
Rapid detection is especially important where preventive or therapeutic measures are needed (intensive care, surgical interventions...). However, current available assays to detect S. aureus, based on coagulase tests with enriched cells, require several hours of analysis (4-24 h).
An immunochemical method for rapid and specific identification of Staphylococcus aureus caused infections has been developed. The assay is based on the use of suitable immunoreagents and polyclonal antibodies able to selectively detect S. aureus cell wall.
This method could be used on different immunochemical analytical configurations, including ELISA microplates, test strips, immunosensors or any other format suitable for further implementation on Point-of-Care (PoC) devices, obtaining better sensitivity and specificity than current methods. In addition, it might allow medical providers to select the most appropriate antibiotic earlier in the course of the infection.
The Spanish research centers are searching for pharmaceutical or diagnostic companies that could be interested in the use of this immunoassay to diagnose S. aureus caused infections, under a patent license. Currently, assay validation is being carried out with endotracheal aspirates (BAS) and bronchoalveolar lavage (BAL) samples of patients infected with this bacterium. Companies interested in this technology should carry out either by themselves or through research collaboration with our organization some further development of the test to reach the market.
The Spanish public entities have broad experience in the development of immunodiagnostics.
Advantages and Innovations:
The main advantages of the developed ELISA test are:
· The system is easy to use, fast (less than 2 hours), inexpensive and labour-saving. Results can be obtained without pre-enrichment of the sample required, which is mandatory in the current analytical methods.
· High sensitivity. Limit of detection (LOD) down to 104 CFU/mL.
· Specificity. Cross-reactivity with other bacteria is negligible.
· It allows routine screening and simultaneous analysis of multiple samples.
· In situ application. Special facilities are not required.
Stage of Development:
Under development/lab tested
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
Priority patent application filed

Partner sought

Type and Role of Partner Sought:
- Type of partner sought: Pharmas, diagnostic or biotech companies interested in diagnostics
- Specific area of activity of the partner: diagnosis, infections
- Task to be performed by the partner sought: final development of the test to reach de market.


Type and Size of Client:
R&D Institution
Already Engaged in Trans-National Cooperation:
Languages Spoken:


Technology Keywords:
06001005 Diagnósticos, diagnosis
06002007 Ensayos in vitro, experimentos
06001018 Virus, virología / antibióticos / bacteriología